🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

226 results for “Pfizer” Clear

  1. "myk-461 capsules, placebo is a solid oral dosage form in size 2 gelatin capsules each containing 120 mg of an excipient blend. it is intended as a placebo to match myk-461 capsules of all active strengths", Mavacamten, Mavacamten, Mavacamten, Mavacamten, Mavacamten

    Bristol-Myers Squibb / Pfizer EEIG

    Symptomatic Obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial

  2. 35 mg oral lyophilisate, 25 mg oral lyophilisate, 50 mg oral lyophilisate, VYDURA 75 mg oral lyophilisate

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Acute Migraine (with or without aura)

    phase 3 small molecule active

    1 trial

  3. 5% Dextrose injection; Solution for injection/infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., 0.9% Sodium Chloride injection; Solution for injection/infusion

    Bristol-Myers Squibb / Pfizer EEIG

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  4. Abrocitinib

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Moderate-to-Severe Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  5. Abrocitinib Placebo, Abrocitinib

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Moderate-to-Severe Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  6. Afinitor 10 mg tablets, Aromasin 25 mg coated tablets, Faslodex 250 mg solution for injection., Afinitor 5 mg tablets

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Hormone receptor-positive, her2-negative advanced/metastatic breast cancer

    phase 3 small molecule active

    1 trial

  7. BEVACIZUMAB, OXALIPLATIN, CALCIUM FOLINATE, FLUOROURACIL, PF-08634404

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  8. BNT327 20 mg ml, BNT327 50 mg ml, PEMBROLIZUMAB

    Bristol-Myers Squibb / Pfizer EEIG

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  9. BNT327 50 mg ml, DURVALUMAB, BNT327 20 mg ml

    Bristol-Myers Squibb / Pfizer EEIG

    Unresectable Stage III non-small cell lung cancer without progression

    phase 3 small molecule active

    1 trial

  10. Bortezomib STADA 2,5 mg/ml Injektionslösung, Dexamethason 0,5 mg JENAPHARM®, Empliciti 400 mg powder for concentrate for solution for infusion., Kyprolis 60 mg powder for solution for infusion, Privigen 100 mg/ml solution for infusion, Privigen 100 mg/ml solution for infusion, Imnovid 1 mg hard capsules, -, Nodexon 20 mg tabletes, Imnovid 3 mg hard capsules, Imnovid 4 mg hard capsules, Imnovid 2 mg hard capsules, Nodexon 20 mg tabletės, ELRANATAMAB, Dexamethason 4 mg JENAPHARM®

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  11. CALCIUM FOLINATE, OPDIVO 10 mg/mL concentrate for solution for infusion., BNT327 20 mg ml, OXALIPLATIN, FLUOROURACIL, BNT327 50 mg ml, CAPECITABINE, CAPECITABINE

    Bristol-Myers Squibb / Pfizer EEIG

    Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  12. CAPECITABINE, Fluorouracil 50 mg/ml Solution for Injection or Infusion, Oxaliplatin 5mg/ml concentrate for solution for infusion, CETUXIMAB, ENCORAFENIB, Calcium Folinate 10 mg/ml Injection, CAMPTO 20 mg/mL concentrate for solution for infusion, Irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion, CAMPTO 20 mg/mL concentrate for solution for infusion, FLUOROURACIL, IRINOTECAN, Bevacizumab, CALCIUM FOLINATE, Capecitabine, Cetuximab, OXALIPLATIN, Oxaliplatin 5mg/ml concentrate for Solution

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Colorectal cancer (BRAF V600E-mutant mCRC)

    phase 3 small molecule active

    1 trial

  13. CARBOPLATIN, CISPLATIN, PEGFILGRASTIM, PEMETREXED, BL-B01D1

    Bristol-Myers Squibb / Pfizer EEIG

    EGFR-mutated Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  14. CISPLATIN, BL-B01D1, GEMCITABINE, PEGFILGRASTIM, CARBOPLATIN

    Bristol-Myers Squibb / Pfizer EEIG

    Metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  15. CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, OPDIVO 10 mg/mL concentrate for solution for infusion., Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, GEMSOL, 40 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI

    Bristol-Myers Squibb / Pfizer EEIG

    Bladder Cancer Muscle-Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  16. Capsule to match PF-06651600 (Ritlecitinib) 50 mg, Ritlecitinib tosilate, DEXAMETHASONE, Capsule to match pf-06651600 (ritlecitinib) 100 mg, Ritlecitinib Tosilate

    Pfizer Ireland Pharmaceuticals Unlimited Company

    NON SEGMENTAL VITILIGO

    phase 3 small molecule active

    1 trial

  17. Cibinqo 100 mg film-coated tablets, Placebo for Abrocitinib 100mg tablet

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Moderate to severe atopic dermatitis

    phase 3 small molecule active

    1 trial

  18. DEXAMETHASONE, Xtandi - 40 mg soft capsules, PF-06821497, DEXAMETHASONE, PF-06821497, PREDNISOLONE, DOCETAXEL

    Pfizer Ireland Pharmaceuticals Unlimited Company

    METASTATIC CASTRATION RESISTANT PROSTATE CANCER

    phase 3 small molecule active

    1 trial

  19. DOCETAXEL

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  20. Deucravacitinib placebo 3 mg film-coated tablets oral use, Deucravacitinib placebo 6 mg film-coated tablets oral use, deucravacitinib, deucravacitinib

    Bristol-Myers Squibb / Pfizer EEIG

    Sjogren's syndrome

    phase 3 small molecule active

    1 trial

  21. ELRANATAMAB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Multiple myeloma

    phase 3 small molecule active

    1 trial

  22. ENCORAFENIB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Binimetinib placebo, BINIMETINIB, Encorafenib Pacebo

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma

    phase 3 small molecule active

    1 trial

  23. ETOPOSIDE, ATEZOLIZUMAB, PF-08634404, CARBOPLATIN

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Extensive-Stage Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  24. ETOPOSIDE, Atigotatug + Nivolumab FDC, CARBOPLATIN, ATEZOLIZUMAB

    Bristol-Myers Squibb / Pfizer EEIG

    Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources